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Cytotoxic gold compounds hold today great promise as new pharmacological agents for treatment of
human ovarian carcinoma; yet, their mode of action is still largely unknown. To shed light on the
underlying molecular mechanisms, we performed 2D-DIGE analysis to identify differential protein
expression in a cisplatin-sensitive human ovarian cancer cell line (A2780/S) following treatment with
two representative gold(III) complexes that are known to be potent antiproliferative agents, namely
AuL12 and Au2Phen. Software analysis using DeCyder was performed and few differentially expressed
protein spots were visualized between the three examined settings after 24 h exposure to the cytotoxic
compounds, implying that cellular damage at least during the early phases of exposure is quite limited
and selective, reflecting the attempts of the cell to repair damage and to survive the insult. The potential
of novel proteomic methods to disclose mechanistic details of cytotoxic metallodrugs is herein further
highlighted. Different patterns of proteomic changes were highlighted for the two metallodrugs with
only a few perturbed protein spots in common. Using MALDI-TOF MS and ESI-Ion trap MS/MS,
several differentially expressed proteins were identified. Two of these were validated by western blotting:
Ubiquilin-1, responsible for inhibiting degradation of proteins such as p53 and NAP1L1, a candidate
marker identified in primary tumors. Ubiquilin-1 resulted over-expressed following both treatments and
NAP1L1 was down-expressed in AuL12-treated cells in comparison with control and with Au2Phen-
treated cells. In conclusion, we performed a comprehensive analysis of proteins regulated by AuL12
and Au2Phen, providing a useful insight into their mechanisms of action.
Introduction
Ovarian cancer is the second among gynecological cancers in
number of new cases and the first among gynecological cancers
in rate of deaths in Western countries.1 It is characterized by
few and nonspecific early symptoms, typically showing up only
in a rather advanced stage, which explains the poor survival of
ovarian cancer patients (i.e. overall 5 year survival is around
45%).2 Platinum-based chemotherapy, such as that using
cisplatin, is the election treatment for human ovarian cancer.
However, despite the relevant contribution of cisplatin in
ameliorating the quality of life and the overall survival of
cancer patients, the occurrence of intrinsic or acquired tumor
chemoresistance remains a major determinant of chemotherapy
failure and of unfavorable clinical outcome.3,4 Because of cisplatin
resistance, several new platinum and non-platinum metal com-
pounds were prepared, characterized and evaluated pharmacologi-
cally as alternative chemotherapeutic agents for ovarian carcinoma
treatment.5 In recent years, research has increasingly focused on
cytotoxic gold compounds as drug candidates.6 In fact, gold(III)
complexes display the same electronic configuration (d8) and
similar structural and reactivity features to platinum(II) complexes7
(in particular a strong preference for square-planar geometry and a
rather favourable kinetic profile) but the respective mechanisms
appear to be drastically different. A number of gold(III) complexes
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were found to possess promising pharmacological profiles in vitro
and in some cases also in vivo.8,9
The present investigation is focused on AuL12, a gold(III)
dithiocarbamate compound that was reported to be particu-
larly effective both in vitro and in vivo,10 and Au2Phen, a
binuclear gold(III) complex that manifested outstanding prop-
erties in vitro when challenged against a large panel of human
tumor cell lines.11 Fig. 1 shows the chemical structure of
AuL12 and Au2Phen.
Remarkably, AuL12 shows higher anticancer activity than
cisplatin itself toward all the murine tumor models, inducing
up to 80% inhibition of tumor growth. In addition, it shows
low acute toxicity levels and reduced nephrotoxicity.10
The application of wide approaches, such as proteomics,
might lead to further progress in understanding the mechan-
isms of action of gold compounds. Proteomic approaches were
recently exploited to investigate the mode of action of anti-
cancer metallodrugs.12–14
Moreover, the introduction of fluorescence-based methodologies
in the 2-DE field has provided a substantial advantage in proteomic
investigations. 2-D DIGE is characterized by a high sensitivity, a
wide linear dynamic range for quantitative accuracy and when
utilizing a sample multiplexing strategy and gel coordination via an
internal standard, a direct quantitative evaluation of changes, as
well as minimization of experimental variation. Accordingly,
DIGE analysis generates highly accurate data with reliable
biological significance.
In our previous proteomic works we showed that various
cytotoxic gold compounds produce their antiproliferative
effects through a variety of molecular mechanisms and that
a number of distinct protein targets are likely involved.15 In
particular, we analyzed proteomic alterations induced by
Auranofin and Auoxo6 in a human ovarian cancer cisplatin-
sensitive cell line (A2780/S) and in its parental resistant cell line
(A2780/R). In both cell lines Auranofin and Auoxo6 caused
relatively modest changes in protein expression in comparison
with controls. Some of the affected proteins are primarily
involved in intracellular redox homeostasis, implying that cell
damage is probably the consequence of severe oxidative stress;
pair wise, proteins that are biomarkers of apoptosis were found
to be greatly perturbed.
We report here the results of a DIGE proteomic study on the
cellular effects of two additional cytotoxic gold compounds,
AuL12 and Au2Phen, by comparing the proteomic profiles of
A2780/S cells treated with those of controls. Applying 2-DDIGE
with dedicated software analysis, few differentially expressed
protein spots were visualized between the control and the two
drug treatments examined, indicating that the two different gold
compounds cause different proteomic modifications. Successive
mass spectrometry application, MALDI-TOF MS and ESI-Ion
trap MS/MS allowed the identification of several differentially
expressed proteins and for the most interesting candidates, the
proteomic analysis was validated by western blotting. Detailed
functional analysis of the altered proteins provides valuable
insight into the possible biochemical mechanisms that are elicited
by AuL12 and Au2Phen.
Results and discussion
Antiproliferative effects of AuL12 and Au2Phen toward
A2780 cells
Cytotoxic effects of AuL12 and Au2Phen against the above
reported human ovarian carcinoma cell lines, A2780/S and
A2780/R, were determined according to the procedure of
Skehan.16 After 72 h of exposure to the two compounds a
relevant cytotoxic activity was observed. CI50 values fell in the
low mM range (Table 1) for both compounds. In particular,
the two compounds were more active than cisplatin against the
resistant cell line and Au2Phen also against the sensitive cell
line. Cross-resistance ratios (r) of the study compounds were
markedly lower (i.e. 1.3 and 4.1 for AuL12 and Au2Phen,
respectively) than that of cisplatin (16.9) (Table 1).
Analysis of 2-D DIGE images of A2780/S gold-treated and
untreated cells
To analyze in detail protein expression modifications induced
by the two gold compounds, quantitative proteomic analysis
of A2780/S gold-treated and untreated cells was performed
according to high-sensitive 2-D DIGE. A2780/S cells were
incubated for 24 h with AuL12 and Au2Phen at a concentration
corresponding to their 72 h exposure CI50 values (4.0 and
0.8 mM, respectively) and protein extracts were subsequently
prepared for DIGE analysis, as previously reported in
‘‘Experimental’’.
Resulting Cydyet-stained gels were analyzed using DeCyder
software. For each condition, triplicate biological repeats were
obtained and reverse labelled by Cy3 and Cy5, while the Cy2 dye
was used for the internal standard. Generated from an equal
combination of all the samples tested in the same experiment, the
standard allows a proper quantitative comparison of proteomic
variations with statistical confidence, as described under ‘‘Experi-
mental’’. A total of 9 samples labelled with Cy3 and Cy5 were
run in five gels along with a pooled standard labelled with Cy2
Fig. 1 AuL12 (A) and Au2phen (B).
Table 1 Antiproliferative activity of AuL12, Au2Phen and cisplatin
against A2780 ovarian carcinoma human cell lines, either sensitive
(A2780/S) or resistant (A2780/R) to cisplatin
A2780/S A2780/R
CI50 (mM)  SD CI50 (mM)  SD
AuL12
Mean 4.0  1.0 5.2  1.3
R 1.3
Au2Phen
Mean 0.8  0.1 3.2  1.6
R 4.1
Cisplatin
Mean 1.6  0.5 26.5  3.1
R 16.9
The experiment was performed in triplicate; R, cross-resistance ratios;
SD, standard deviation.
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giving a total of 14 images. For samples resolved in the same gel,
quantification of the proteins was performed first by dividing the
Cy3 or Cy5 signals by the Cy2 intensities, and then these intragel
ratios were compared with the ratios from other gels. Thus, for a
given protein, the normalized abundance ratios from all
9 samples can be intercompared in an five-gel experiment as
the protein spot intensity in every gel is normalized to the same
internal standard. To compute the fold changes in protein
expression between the groups and their statistical significance,
once the standardized abundance ratios for spots in every gel
were computed, the corresponding Cy3 and Cy5 spot maps for 9
samples were grouped according to the group description as
described in the experimental design (Table 2).
According to the DeCyder software analysis, about 2500
protein spots were constantly detected in each gel and quanti-
fied, normalized and inter-gel-matched. Due to the CyDye
DIGE Fluor detection limit and the CyDye linear response in
protein concentrations over five orders of magnitude, 26 protein
spots had significant differences occurring between the untreated
control cells and the two different settings of drug-treated cells. In
Fig. 2, a representative 2-D DIGE spot map of AuL12-treated
A2780/S cells is reported, showing all the differences found
between the two different drug-treatments and the control.
Protein expression changes were considered significant when
their quantity decreased or increased by at least 1.3-fold. In
order to find proteic differences characteristics of each gold-
compound we performed a univariate analysis (AuL12 vs. control;
Au2Phen vs. control) with a two tailed Student’s t-test, p r 0.05
and was statistically supported by a one-way ANOVA (p-valueo
0.05). In order to find proteic differences in common between the
two treatments, we performed a one-way ANOVA, pr 0.05.
Remarkably, both AuL12 and Au2Phen treatments caused
small modifications of protein expression profiles. Only a
limited number of protein spots manifested appreciable down-
or up-regulation. According to our statistics, among the detected
biological variations, 8 protein spots (5 down-regulated and 3
up-regulated) and 10 protein spots (2 down-regulated and 8
up-regulated) had significantly changed volume values after
AuL12 and Au2Phen treatment, respectively, as compared to the
Table 2 Experimental design for 2-D DIGE proteome profiling.
Three biological replicate samples for each group (C1–C2–C3: control
replicates; A1–A2–A3: AuL12 samples; B1–B2–B3: Au2Phen samples)
were used and labelled with Cy3 or Cy5. Each gel contained the pooled
standard (equal aliquots of all the samples in all groups) and two other
subject samples. Thus, the 14 samples were analyzed by running five
gels. (For detailed description refer to ‘‘Experimental.’’)
Gel Cy3 Cy5 Cy2
1 C1 B1 Pooled internal standard sample
2 A1 C2 Pooled internal standard sample
3 C3 A2 Pooled internal standard sample
4 B2 A3 Pooled internal standard sample
5 B3 Pooled internal standard sample
Fig. 2 Representative Cy3-labeled spot map of A2780/S cells treated for 24 h with AuL12. All the detected differences between the control cells
and the two drug-tested conditions are visualized by black circles. We used white circles when the image was too dark for black ones. For
MS-identified protein spots, the spot numbers match those listed in Tables 3 and 4.
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control group. In addition, 8 protein spots (1 down-regulated and
7 up-regulated) were detected as differentially expressed after both
treatments, when compared with control cells. The locations of
these protein spots are marked with black and white circles in the
representative gel shown in Fig. 2.
Principal component analysis (PCA)
In addition to univariate analysis, multivariate analyses were
performed to explore categories of differential protein expression.
To examine relationships existing between the three tested con-
ditions and to corroborate the biological validity of the BVA
results (see ‘‘Experimental’’ for analyses details), acquired data
were processed in an unsupervised manner, using multivariate
analysis methods according to the DeCyder EDA module.
Protein spots included in the analyses were those present in
80% of the spot maps and with expression variation of at least
1.3-fold at the 95th confidence level (one-way ANOVA, p r
0.05). The Principal Component Analysis (PCA) revealed distinct
expression profiles between drug-treated and untreated A2780/S
cells (Fig. 3). PCA demonstrated consistent reproducibility
between the biological triplicates, as spot maps properly segregated
into three experimental groups (encircled by different colours)
that are clearly separated from each other in the PCA plot.
The first principal component (PC1) accounted for 54.1% of
the variance in the data, while the second principal component
(PC2) accounted for an additional 24.5% of the variation.
Proteomic profiles of treated and control cells
Interesting spots were excised from preparative SyproRuby
stained 2-DE gels loaded with 800 mg of total proteins for
protein identification by tryptic in-gel digestion and MALDI-TOF
MS and/or LC-MS/MS analysis. Following a Mascot engine
search, using the acquired MS data, 16 spots were identified. Not
all spots could be identified because of the relatively low protein
concentrations and MS sensitivity limitations. Positions of the
identified spots are indicated by numbers in the representative gels
Fig. 3 The protein expression profiles of experimental groups were visualized in two-dimensional Euclidian space by using the extended data
analysis module of DeCyder software as described under ‘‘Experimental’’. PCA distinctly clustered the 9 individual samples into three
experimental groups corresponding to the three experimental conditions (Control; AuL12 and Au2phen).
Table 3 Mass spectrometry identified proteins
Spot no ACa Protein name
MASCOT search results Fold changee
No. of
matched peptideb
Sequence
coverage%c Scored
AuL12/
control
Au2Phen/
control
1 P61978 Heterogeneous nuclear ribonucleoprotein K 10 24 89 1.63
2 Q14257 Reticulocalbin-2 8 34 135 1.68
3 Q9NQR4 Omega-amidase NIT2 11 41 176 1.42
4 P55209 Nucleosome assembly protein 1-like 1 6 22 103 1.54
5 P07437 Tubulin beta chain 20 43 224 1.40
6 Q9Y3F4 Serine–threonine kinase receptor-associated protein 8 32 121 1.35
7 P24534/P62258 Mix Elongation factor 1-b/14-3-3 7/9 46/31 90/74 1.45
8 P12004 Proliferating cell nuclear antigen 11 47 132 1.45
a Swiss-Prot/TrEMBL accession number. b Number of peptide masses matching the top hit from Ms-Fit PMF. c Percentage of amino acid
sequence coverage of matched peptides in the identified proteins. d MASCOTscore (Matrix Science, London, UK; http://www.matrixscience.com).
e Fold change (AuL12 vs. control and Au2Phen vs. control) was calculated dividing %V from AuL12 or Au2Phen by the %V from control.
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shown in Fig. 2. A list of the up- and down-regulated proteins is
given in Tables 3 and 4. Tables report all identified proteins,
protein name, NCBI database accession number, Mascot score,
peptide matched, sequence coverage and statistical analysis (fold
change 1.3 and p-valueo 0.05). In particular Table 3 indicates
proteins found as differences following a single treatment, while
Table 4 indicates proteins found as differences in common
between the two treatments. A group of 4 protein spots (4, 5,
6, 8) shows a significant down-regulation in AuL12-treated cells
versus controls. One protein spot (7) shows an increase in the
intensity level. The volume of 3 protein spots (1, 2, 3) was
significantly up-regulated in the Au2Phen-treated cells with a
p-value ranging between 0.05 and 0.005 when compared with the
control group. Among the identified protein spots we found
1 spot down-expressed in both treatments (11) and 7 proteins
up-regulated (9, 10, 12, 13, 14, 15, 16).
Proteins over-expressed in Au2Phen treated cells
We identified by mass spectrometry Heterogeneous nuclear
ribonucleoprotein K (Spot 1) as up-regulated in Au2Phen
treated cells. This protein belongs to the family of hnRNPs,
RNA binding proteins that appear to influence pre-mRNA
processing and mRNAmetabolism and transport. This protein is
located in the nucleoplasm and it seems to have a role during the
cell cycle progression. Hope and Murray defined the expression
profile of Heterogeneous nuclear ribonucleoproteins in colorectal
cancer and they showed that there are significant alterations in
both expression and subcellular localization of individual hetero-
geneous nuclear ribonucleoproteins in this type of tumor.17 We
also found an over-expression for Reticulocalbin-2 (RCN) (Spot 2).
This protein does not have known function but its expression
may be related to differential diagnoses of some types of
tumors, although an extensive distribution of RCN has been
demonstrated in various normal organs.18 We found an over-
expression of omega-amidase NIT2 (Spot 3), largely distributed
in nature, that has been suggested to be a tumor suppressor
protein. Its role is to remove potentially toxic intermediates by
converting a-ketoglutaramate and a-ketosuccinamate to biologi-
cally useful a-ketoglutarate and oxaloacetate, respectively. Some
authors report the crucial role of NIT2 in nitrogen and sulfur
metabolism, and the possible link of NIT2 to cancer biology.19
Proteins over-expressed in AuL12 treated cells
In one spot (Spot 7), showing a significant positive correlation
with AuL12 treatment, we identify by mass spectrometry two
proteins: the Elongation factor 1-b and the 14-3-3 protein
epsilon. The first protein is involved in the biosynthesis of
proteins from mRNA molecules. The second is an adapter
protein implicated in regulation of a large spectrum of both
general and specialized signaling pathways.20
Proteins down-expressed in AuL12 treated cells
We observed a reduced expression pattern of Nucleosome
assembly protein 1-like 1 (NAP1L1) (Spot 4). It is involved
in modulating chromatin formation and it contributes to
regulation of cell proliferation. It is a candidate marker
identified by transcriptional profiling in primary tumors and
metastases and in carcinomas. The ability to determine the
malignant potential of these tumors and their propensity to
metastasize provides a biological rationale for the manage-
ment of carcinoids and may have prognostic utility.21 Among
proteins down-expressed in AuL12 treated cells we found
tubulin beta chain (TBB5) (Spot 5). It is a protein associated
with chemotherapeutic responses. In chemoresistant tissues,
tubulin a-1A chain was over-expressed. This protein may be
useful as predictive of chemoresistance.22 Also serine–threonine
kinase receptor-associated protein (STRAP) (Spot 6) has been
found down-expressed. It plays an essential role in spliceosomal
snRNP assembly in the cytoplasm and it is required for pre-
mRNA splicing in the nucleus. A correlation between STRAP
over-expression and various cancers has been identified and it is
becoming clear that STRAP regulates several distinct cellular
processes and modulates multiple signaling pathways.23
The proliferating cell nuclear antigen (PCNA) (Spot 8) is
down-expressed after AuL12 treatment. This protein is involved
in control of eukaryotic DNA replication, inducing a robust
stimulatory effect on DNApolymerase activity.24
Proteins over-expressed following both treatments
Thymidylate kinase (Spot 9) is one of the essential enzymes
involved in the pyrimidine synthesis. Romain et al. investigated
its relationship with breast cancer. They measured thymidine
kinase (TK), thymidylate synthase (TS) and thymidylate kinase
Table 4 Mass spectrometry identified proteins in common between the two treatments
Spot no ACa Protein name
MASCOT search results
Fold
changee
One-way-
ANOVA
No. of
matched peptideb Sequence coverage%c Scored
9 P23919 Thymidylate kinase 10 44 122 1.41 0.042
10 P49773 Histidine triad nucleotide-binding protein 1 7 65 114 1.33 0.030
11 P28838 Cytosol aminopeptidase 2 TIQVDNTDAEGR 45/33 1.35 0.044
12 P63104 14-3-3 protein zeta/delta 6 SVTEQGAELSNEER 65/32 1.44 0.046
13 P60709 Actin, cytoplasmic 1 11 21 130 1.61 0.041
14 P14174 Macrophage migration inhibitory factor 2 PMFIVNTNVPR 48/32 1.39 0.025
15 Q9UMX0 Ubiquilin-1 4 FQQQLEQLSAMGFLNR 83/31 1.37 0.030
16 P62937 Peptidyl-prolyl cis–trans isomerase A 8 56 120 1.49 0.032
a Swiss-Prot/TrEMBL or NCBInr accession number. b Number of peptide masses matching the top hit from Ms-Fit PMF. c Percentage of amino acid
sequence coverage of matched peptides in the identified proteins. Reported sequence peptide correspond to one of those resulted fromMS/MS analysis
after ambiguous identifications by MALDI-ToF in that spot. d MASCOTscore (Matrix Science, London, UK; http://www.matrixscience.com).
e Fold change [Au2Phen+AuL12] vs. [Control] was calculated dividing %V from AuL12 and Au2Phen by the %V from control.
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(TMK). Among the enzymes analyzed, only TK demonstrated a
strong correlation with the most aggressive tumors. In contrast,
TS and TMK were not associated with prognosis and metastasis
formation.25 We found histidine triad nucleotide-binding protein
1 (Hint1) (Spot 10). It is a member of the evolutionarily
conserved family of histidine triad proteins that acts, with a
poorly defined molecular mechanisms, as a haplo-insufficient
tumor suppressor. Consistent with a tumor suppressor function,
in the human non-small cell lung cancer cell line NCI-H522, a
reduced expression of Hint1, was observed and its re-introduction
resulted in cell growth inhibition and reduced tumorigenicity.
Moreover Hint1 is involved in regulation of apoptotic pathways
by inducing an up-regulation of p53 expression.26 We found
14-3-3 Protein Zeta/delta (Spot 12) as over-expressed: it belongs
to the 14-3-3 proteins family that have been shown to regulate
many important cellular mechanisms. However, the expression of
14-3-3 isoforms still remains unknown.27 We found an over-
expression of peptidyl-prolyl cis–trans isomerase A (PPI1A or
cyclophilin A) (Spot 16); this protein belongs to the family of
PPIases whose activity is to accelerate the proteins folding. PPI1A
has been reported to be upregulated in diverse human cancers and
its over-expression induces resistance to chemotherapeutic agents
such as cisplatin in cancer cells.28 Also the macrophage migration
inhibitory factor (MIF) (Spot 14) has been found to be over-
expressed. It is a pro-inflammatory cytokine involved in the innate
immune response. The expression ofMIF at sites of inflammation
suggests a role as mediator in regulating the function of macro-
phages in host defense.29 We found an over-expression of
Ubiquilin-1 (Spot 15), responsible for the inhibition of protea-
some-mediated protein degradation. In particular, Patel et al.
observe that Ubiquilin-1 is responsible for inhibiting proteasome-
mediated protein degradation in a range of proteins, such as p53,
cyclin A and IkB.30
Protein down-expressed in both treatments
The only protein identified whose expression resulted down-regu-
lated following both treatments is the cytosol aminopeptidase
(Spot 11). It is involved in processing and regular proteins turnover.
This protein catalyzes the removal of unsubstituted N-terminal
amino acids from various peptides and it is involved in the
proteasome/ubiquitin pathway. Its down-expression, inhibiting
protein turnover, could result in cell apoptosis and it could
represent a novel therapeutic approach.31
Validation of differentially expressed proteins by
immunoblotting
To validate the DIGE/MS-obtained results, as well as to
further evaluate the nature and importance of some of the
identified proteins that changed expression after drug treat-
ment, mono-dimensional (1D) western blotting analyses were
performed. Proteins with identified expression changes were
selected for immunoblotting analysis according to their known
or supposed involvement in the biochemical pathways affected
by the evaluated drugs, based on the available literature. For
these analyses, a new experiment was performed on A2780/S
cells either untreated or treated for 24 h with AuL12 and
Au2Phen. Two proteins, Ubiquilin-1 and NAP1L1, were
validated by western blotting. As shown in Fig. 4, NAP1L1
is down-expressed in AuL12-treated cells in comparison with
control and in comparison with Au2Phen-treated cells.
Ubiquilin-1 resulted over-expressed following both treatments
in comparison with control. The protein expression-fold
changes are consistent with the reported 2-D DIGE results.
Experimental
Materials and reagents
Au2Phen was synthesized as described by Cinellu et al.
11 The
gold(III) complex AuL12 was synthesized and purified as
previously described.32 All other chemicals were of analytical
grade. RPMI 1640 cell culture medium, fetal calf serum (FCS)
and phosphate-buffered saline were obtained from Celbio
(Milan, Italy); sulforhodamine B (SRB) was obtained from
Sigma (Milan, Italy).
Cell lines and cell culture
The human ovarian carcinoma cell line sensitive to cisplatin
(A2780/S) and its cisplatin-resistant cell subline (A2780/R)
were used for cytotoxicity studies and the A2780/S subline for
proteomic studies. Cell lines were maintained in RPMI1640
Fig. 4 Validation of proteomic results by western blot analysis. Western blots were probed with antibodies against NAP1L1 and Ubiquilin-1
proteins identified by proteomic screening. The intensity of immunostained bands was normalized with the total protein intensities measured from
the same blot stained with Coomassie brilliant blue (in panel A and panel B a representative band of the lane is reported). (A) AuL12-induced
reduced expression of NAP1L1 after 24 h of treatment. (B) AuL12-induced and Au2Phen-induced increased expression of Ubiquilin-1 after 24 h of
treatment. (C) Histograms representing NAP1L1 and Ubiquilin-1 protein expression variation. The two-tailed non-paired Student’s t-test was
performed using ORIGIN 6.0 (p o 0.05).
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medium supplemented with 10% of FCS and antibiotics at
37 1C in a 5% CO2 atmosphere and subcultured twice weekly.
Cell growth inhibition studies
The cytotoxic activity of AuL12 and Au2Phen was evaluated
against the A2780/S and A2780/R cell lines according to the
procedure described by Skehan.16 Both compounds were
diluted in DMSO as stock solutions (10 mM). Exponentially
growing cells were seeded in 96-well microplates at a density of
5  103 cells per well. After cell inoculation, the microtitre
plates were incubated under standard culture conditions
(37 1C, 5% CO2, 95% air and 100% relative humidity) for
24 h prior to the addition of study compounds. After 24 h, the
medium was removed and replaced with fresh medium con-
taining drug concentrations ranging from 0.003 to 100 mM for
a continuous exposure of 72 h for both compounds tested. For
comparison purposes the cytotoxic activity of cisplatin against
the A2780/S and A2780/R cells, measured under the same
experimental conditions, was also determined. Then cells were
fixed with 100 mL of ice-cold 10% trichloroacetic acid (TCA)
for 60 min at 4 1C, rinsed 6 times with water and air-dried.
Fixed cells were stained with 50 mL of sulforhodamine B
(SRB) solution (0.4% SRB/0.1% acetic acid), rinsed with
0.1% acetic acid and air-dried. At the end of the staining
period, SRB was dissolved in 150 mL of 10 mM Tris–HCl
solution (pH 10.5) for 10 min in a gyratory shaker. Optical
density was read in a microplate reader interfaced with the
software Microplate Manager/PV version 4.0 (Bio-Rad
Laboratories, Milan, Italy) at 540 nm. The CI50 drug concen-
tration resulting in a 50% reduction in the net protein content
(as measured by SRB staining) in drug-treated cells as compared
to untreated control cells was determined after 72 h of drug
exposure. The reported CI50 data represent the mean of at
least three independent experiments.
Sample preparation and labelling with CyDyes
Whole protein extracts were obtained from A2780/S cells and
A2780/S cells treated with AuL12 and Au2Phen. Briefly, cells
were seeded in tissue-culture plates at 5  104 cells mL1 (total
volume 30 mL) and incubated overnight, then exposed to
concentrations of the study compounds equal to 72 h exposure
CI50 values for 24 h. At the end of incubation cells were
washed with phosphate-buffered saline, then were scraped in
RIPA buffer [50 mM Tris–HCl pH 7.0, 1% NP-40, 150 mM
NaCl, 2 mM ethylene glycol bis(2-aminoethyl ether)tetraacetic
acid, 100 mM NaF] containing a cocktail of protease inhibitors
(Sigma). Cells were sonicated (10 s) and protein extracts were
clarified by centrifugation at 8000g for 10 min. Proteins were
precipitated following a chloroform/methanol protocol and
pellets obtained were then resuspended with lysis DIGE buffer
(7 M urea, 2 M thiourea, 4% (w/v) CHAPS and 25 mM Tris).
Protein concentration was estimated by Bradford’s assay33
and as the protein concentration was more than 5 mg mL1 for
all the samples, we proceed with the fluorescence dye labelling.
Minimal protein labeling for 2-D DIGE was performed
according to the manufacturer’s instructions (GE Healthcare).
It was prepared as an internal standard resulting from pooling
aliquots of the nine experimental samples, which was labelled
with the fluorescent cyanine dye Cy2. Samples from A2780/S
cells untreated and treated with AuL12 or Au2Phen were
labelled with Cy3 or Cy5 cyanine dyes by the addition of
480 pmol of CyDye in 1.2 mL of anhydrous N,N-dimethylform-
amide per 60 mg of protein. An alternate dye labelling was used
such that the three samples for any condition were variously
labelled with Cy3 or Cy5 to avoid any dye-specific staining
bias. Labelling incubation was performed on ice in the dark for
30 min; then the reaction was stopped by the addition of 10 mM
lysine on ice for 10 minutes. Cy3 and Cy5 quenched samples,
according to the experimental design (Table 1), were mixed
together with an aliquot of Cy2 labelled standard and an equal
volume of 2DIGE buffer (7 M urea, 2 M thiourea, 4% (w/v)
CHAPS and 2% (w/v) DTE). Previous to isoelectric focusing
(IEF), the total volume was increased to 450 mL with 1
DIGE rehydration solution (7 M urea, 2 M thiourea, 4% (w/v)
CHAPS and 1% (w/v) DTE) and loaded on commercial
nonlinear wide-range immobilized pH gradients (IPGs;
pH 3.0–10; 24 cm long IPG strips; Biorad).
DIGE two dimensional gel electrophoresis
The first dimension (IEF) was achieved using an Ettan IPG-
phort system (GE Healthcare). Runs were performed at 16 1C
in the dark, until a total of 80 000 V h1 were reached. Focused
strips were equilibrated in 6 M urea, 2% (w/v) SDS, 2% (w/v)
DTE, 30% (v/v) glycerol and 0.05 M Tris–HCl pH 6.8 for
12 min and subsequently for 5 min in the same urea/SDS/
Tris–HCl buffer solution where DTT was substituted with
2.5% iodoacetamide. The second dimension was carried out at
15 1C on 9–16% polyacrylamide linear gradient gels (24 cm 
20 cm  1 mm) at 17 W/gel constant Watt using an Ettan Dalt
II system (GE Healthcare). Runs were performed until the dye
front reached the bottom of the gel, in accordance with
Hochstrasser et al.34 All electrophoresis procedures were
performed in the dark.
Image analysis
DIGE gel images were acquired by the Typhoon 9400 imager
(GE Healthcare). All gels were scanned at 100 mm resolution.
Data analysis was carried out using DeCyder 2D v7.0 Soft-
ware (GE Healthcare). A total of 14 gel images consisting of
three biological replicate images from A2780/S cells untreated,
three replicates from A2780/S cells treated with AuL12, three
replicates from A2780/S cells treated with Au2Phen and five
replicates from the internal standards were processed. Quan-
tification of spot intensity data was performed by the differ-
ential in-gel analysis (DIA) module of DeCyder software: all
spots from each gel were detected and normalized volume
ratios for each protein were calculated by using the individual
signal of pooled-sample Cy2-labelled as an internal standard.
The biological variation analysis (BVA) module allowed samples
to be inter-compared along with the experimental design by
the univariate analysis across the five gels. Protein spot variation
was considered significant if the normalized spot volume showed
at least 1.3 fold change and a p-value o 0.05 (two tailed
Student’s t-test). Protein spots that satisfy these parameters were
signed as protein of interest. We also performed a multivariate
analyses, using the extended data analysis (EDA) module, to
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highlight proteins with similar expression patterns among the
three experimental conditions, p-valueo 0.05 (one way ANOVA).
Relationships among spot maps were visualized by performing
a principal component analysis (PCA) according to the intensity
values of protein spots marked as protein of interest in the BVA
module. All spot maps were distributed in a two-dimensional
space, along with the first two principal components, PC1 and
PC2, that represented the largest sources of variation in the
experimental data set.
Mass spectrometry MALDI-TOF and LC-ESI/MS-MS
MS-preparative IPG strips (24 cm non-linear pH 3–10, Biorad)
were rehydrated with 450 mL of 1 DIGE rehydration solution
and 2% v/v Pharmalyte pH 3–10 (GE Healthcare), for 12 h at
room temperature using a re-swelling tray (GE Healthcare). For
MS-preparative gels, 800 mg of total proteins, obtained by
pooling all our conditions, were loaded on both cathodic and
anodic ends of the IPGphor Cup Loading Strip Holders
(GE Healthcare). Runs were performed at 16 1C, until a total
of 110 000 V h1 for strip were reached. Strip equilibration and
second dimension were performed as described above for the
DIGE runs. MS-preparative gels were stained with SYPRO
Ruby (Biorad) according to the manufacturer’s instructions.
The internal surface of the inner low fluorescence plate was
previously treated with Bind-Silane (g-methacryloxypropyltri-
methoxysilane; LKB-Produkter AB, Brommo, Sweden), air
dried for 1 h to covalently attach polyacrylamide gels subjected
to SYPRO Ruby staining and automatic cutting by Ettan Spot
Picker (GEHealthcare). Protein identification was mainly carried
out by peptide mass fingerprinting (PMF) on an Ettan MALDI-
ToF Pro mass spectrometer (GE Healthcare) as previously
described.35–37 After visualization by an SYPRO Ruby staining
protocol, all the spots of interest were mechanically excised,
destained in 2.5 mM ammonium bicarbonate and 50% aceto-
nitrile and finally dehydrated in acetonitrile. They were then
rehydrated in trypsin solution and in-gel protein digestion was
performed by overnight incubation at 37 1C. Each protein digest
(0.75 mL) was spotted onto the MALDI target and allowed to air
dry. Then 0.75 mL of matrix solution (saturated solution of
a-cyano-4-hydroxycinnamic acid in 50% (v/v) acetonitrile and
0.5% (v/v) TFA) was applied to the sample which was then
dried again. Mass spectra were acquired automatically using the
Ettan MALDI Evaluation software (GE Healthcare). Spectra
were internally calibrated using the autoproteolysis peptides
of trypsin (842.51 and 2211.10 Da). PMF searching was carried
out in UniProtKB databases using MASCOT (Matrix Science
Ltd, London, UK, http://www.matrixscience.com). Taxonomy
was limited to Homo sapiens, a mass tolerance of 100 ppm was
allowed and the number of accepted missed cleavage sites was set
to one. Alkylation of cysteine by carbamidomethylation was
considered a fixed modification, while oxidation of methionine
was considered as a possible modification. The criteria used to
accept identifications included the extent of sequence coverage, the
number of matched peptides and a probabilistic score. Tryptic
digests that did not produce MALDI-TOF unambiguous identi-
fications were subsequently subjected to peptide sequencing on a
nanoscale LC-ESI/MS-MS, as described in detail by Meiring
et al.37 All the analyses were carried out on an LC-MS system
consisting of a PHOENIX 40 (ThermoQuest Ltd., Hemel
Hempstead, UK) and an LCQ DECA IonTrap mass spectro-
meter (Finnigan, SanJose, CA, USA). The peptides, after a
manual injection (5 mL) in a six-port valve, were trapped in a
C18 trapping column (20 mm  100 mm ID  360 mm OD,
Nanoseparations, Nieuwkoop, NL) using a 100% solvent A
(HPLC grade water + 0.1% (v/v) formic acid) under a flow
rate of 5 mL min1 for 10 min. A linear gradient up to 60%
solvent B (acetonitrile + 0.1% (v/v) formic acid) for 30 min
was used for analytical separation and, using a pre-column
splitter restrictor, we obtained a column flow rate of
100–125 nL min1 on a C18 analytical column (30 cm  50 mm
ID  360 mm OD, Nanoseparations). Before the injection of the
next sample, both the trapping and analytical column were
equilibrated for 10 min in 100% solvent B and for 10 min in
100% solvent A. The ESI emitter, a gold-coated fused silica (5 cm
25 mm ID  360 mm OD, Nanoseparations), was heated to
195 1C. A high voltage of 2 kV was applied for stable spray
operation. The LC pump, the mass spectrometer as well as the
automatic mass spectra acquisitions were controlled using the
Xcaliburtm 1.2 system software (Thermo). The MS/MS ions
search was carried out in UniProtKB databases usingMASCOT.
Taxonomy was limited to Homo sapiens, peptide precursor
charge was set to 2+ or 3+, mass tolerance of 1.2 Da for
precursor peptide and 0.6 Da for fragment peptides was
allowed and the number of accepted missed cleavage sites was
set to one. Alkylation of cysteine by carbamidomethylation
was taken as a fixed modification, while oxidation and phos-
phorylation were considered as possible modifications. We
consider significant peptides with individual ion scores (10 
log[P], where P is the probability that the observed match is a
random event) that indicate identity (p o 0.05).
Western blotting analysis of proteomic candidates
Cell conditions were the same as those of the DIGE experi-
ments. Samples (30 mg) were separated by 12% SDS-PAGE
and transferred onto a PVDF membrane (Millipore). To
confirm the results obtained from 2D-DIGE analysis, the
relative amount of NAP1L1 and Ubiquilin-1 proteins were
assessed by Western blot with appropriate monoclonal anti-
bodies (TemaRicerca). For quantification we used blots that
were stained with Coomassie brilliant blue R-250 and sub-
jected to densitometric analysis using Quantity One Software
(Bio-Rad). Statistical analysis of the data was performed by
Student’s t-test; p-values 0.05 were considered statistically
significant. The intensities of the immunostained bands were
normalized with the total protein intensities measured by
Coomassie brilliant blue R-250 from the same blot.
Conclusions
Our study is one of the few works that have investigated in
detail the interaction of two pro-drugs using a wide, quantitative
proteomic approach. Proteomics methods have the potential to
provide specific insight into the alterations induced by drugs on
protein expression. In turn, the observed proteomic alterations
may be related to the modes of action of the drugs themselves.
We have used such an approach to investigate the molecular
mechanisms through which two cytotoxic gold based drugs
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i.e. AuL12 and Au2Phen cause their biological effects. Our
proteomic results suggest the putative targets of these compounds.
In particular we found that both treatments cause an over-
expression of Ubiquilin-1 involved in inhibiting protein degrada-
tion. The cytotoxic effects of the two gold-compounds could be
related to an impairment of protein degradation pathway. Com-
paring these results with the previously reported15 we notice that
the functions of some proteins could be correlated. The first
correlation is between two proteins that are involved in RNA
processing. In A2780/S cells treated with AuL12 we observed a
down-regulation of the STRAP (Spot 6) which plays a role in the
cellular distribution of the complex required for pre-mRNA
splicing. Otherwise in the same cells treated with Auoxo 6 and
Auranofin15 we found down regulated the heterogeneous nuclear
ribonucleoprotein H, a component of the heterogeneous nuclear
ribonucleoprotein (hnRNP) complexes which mediates pre-
mRNA alternative splicing regulation. The second correlation
we found is between two proteins involved in connections of
cytoskeletal components to membrane. In this paper we identified
as overexpressed the protein Ubiquilin-1 (Spot 15) that links
CD47 to the cytoskeleton and promotes the surface expression
of GABA-A receptors. In the previous work, we found an over-
expression of the protein Ezrin, required in epithelial cells for the
formation of microvilli and therefore involved in connections of
major cytoskeletal structures to the plasma membrane. Further
differential proteomics analysis likely using different cancer cell
lines will be necessary to identify common trends among gold(III)
complexes and with respect to gold(I). Extending the analysis to
the transcription level will better explain whether the observed
differences in protein amounts are caused by transcriptional or
post-translational events. Overall, these findings may contribute to
elucidate the molecular mechanisms of the tested drugs and offer
insight into their respective modes and sites of biological action.
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